Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

Background: This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients during the compassionate use program in Spain from Februa...

Full description

Bibliographic Details
Main Authors: Luis Manso, Cristina Hernando, María Galán, Mafalda Oliveira, Miguel A. Cabrera, Raquel Bratos, César A. Rodríguez, Manuel Ruiz-Borrego, Salvador Blanch, Antonio Llombart-Cussac, Juan I. Delgado-Mingorance, Iñaki Álvarez-Busto, Isabel Gallegos, Lucía González-Cortijo, Serafín Morales, Elena Aguirre, Blanca A. Hernando, Ana Ballesteros, José E. Alés-Martínez, Cristina Reboredo, Amparo Oltra, María González-Cao, Marta Santisteban, Diego Malón, Isabel Echeverría, Elisa García-Garre, Estela Vega, Sònia Servitja, Raquel Andrés, Carlos E. Robles, Rafael López, Elena Galve, María J. Echarri, Marta Legeren, Fernando Moreno
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Breast
Subjects:
Advanced breast cancer
Palbociclib
CDK4/6 inhibitors
Endocrine therapy
Compassionate use program
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620302113

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620302113

Similar Items